Mobile Motivational Messages for Change (3M4Chan) Intervention in TMU

About 100 (50 from TMU Hospital and 50 from Wellcome Clinic) current smokers will be recruited who contact smoke cession clinics in teaching hospitals of Taipei Medical University (TMU) and Wellcome Clinic. They will be randomly assigned either to Usual Care (UC) or Usual Care plus 3M4Chan Intervention group (IG). A randomized comparative effectiveness trial will be conducted. Patient will enroll from September 2017 to May 2018. In UC group, the physician provides a brief advice to quit during first consultation, a quit plan template, and medication prescription (Varenicline, Bupropion, Champix, Nicotinell TTS20) as decided by the physician. IG group includes UC plus a mobile App that is programmed to push tailored messages for health concern and readiness to quit, tips for sustaining abstinence, use of interactive self-assessments, helpful cessation information. This group of smokers will benefit from tailored cessation interventions with integrated body weight management elements that take into consideration the prevailing local and cultural influences on diet and levels of physical activity. IG will be continued even after stopping of the UC.

Study Overview

• Status: Completed
• Conditions: Explore Successful Method to Quit Smoking
• Intervention / Treatment: Other: Case

• Study Type: Interventional
• Enrollment (Actual): 92
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan, 11031
    • Syed Abdul Shabbir

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Age 20 years or older and approach smoke cessation clinic at TMU hospital
• Have an Android mobile phone
• Able to read Traditional Chinese
• Willing to participate in all study components
• Willing to be followed-up for 6 months
• Smoked at least once every month in the last two years
• Current smoker

Exclusion Criteria:

• • Below 20 years on the day of enrolment

  • Not willing to participate in the study
  • Those who do not have Android mobile phone or unable to read Mandarin
  • Not willing to share medical information from EHR
  • Subjects who develop adverse effects related to the pharmacological treatment included in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Case; Motivational message will be administrated.	Other: Case; Motivational message will be administrated.
No Intervention: Control; Motivational message will not be administrated.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Smoking cessation rate at two months	Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.	Up to 2 months
Smoking cessation rate at four months	Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.	Up to 4 months
Smoking cessation rate at six months	Smoking cessation rate will be measured as the ratio of the total number of patients who relapsed with total number of patients in their group. Patients will be considered to have relapsed if they fail at least one of their urine cotinine and carbon monoxide tests.	Up to 6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
User engagement at an individual level	Engagement at individual level will be assessed based on the rate of read messages by the patients. This is calculated as the quotient between the messages the patients have read, and the total number of messages the system has sent to the patients. This metric will be assessed throughout the observation until its end.	Up to 6 months
Engagement at aggregated level - Mobile application rolling retention	The percentage of users still active N days after installation. This is a ratio of the number of users whose last day of activity is past day N to the number of users who could have been active on day N. This metric will be assessed throughout the observation until its end.	Up to 6 months
Engagement at aggregated level - Mobile application session length distribution	The session length is defined as the length of time between the start of the application event and the end of the application event. The session length determines the engagement as it is relevant to know how much time patients spend in the app per session. This metric will be assessed throughout the observation until its end.	Up to 6 months
Engagement at aggregated level - Mobile application session frequency	The session frequency is a measure of how often each unique patient used the app within a given time interval. This metric will be assessed throughout the observation until its end.	Up to 6 months
Engagement at aggregated level - Mobile application sessions per user	A session is one use of the mobile application by a patient. This begins when the application is launched and ends when the application is terminated. This metric will be assessed throughout the observation until its end.	Up to 6 months
Engagement at aggregated level - Mobile application return rate	Return rate measures the percentage of patients who return to the app on a specific time after installation. It is measured by cohort group - that is, based on when patients first opened the app. It is calculated as the ratio of the number of users active on a given period to the size of the cohort. This metric will be assessed throughout the observation until its end.	Up to 6 months
User quitting attempts	Number of quitting attempts per patient, including the frequency of the quitting attempts.	Up to 6 months
User app behavior	It will be measured as the time spent per app section.	Up to 6 months
User satisfaction with messages	Patients' answers to a satisfaction questionnaire that will be handed to them at the end of the study.	At 6 months after enrolment.
User message ratings	User's votes for each message in a 5 star scale.	Up to 6 months
User lifestyle feedback	Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaire EQ-5D-5L.	At enrollment and at 6 months after enrollment
User lifestyle feedback	Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaire IPAQ for physical activity.	At enrollment and at 6 months after enrollment
User lifestyle feedback	Comparison of changes in user lifestyle (at baseline and after 6 months) through the combined questionnaires SF-36.	At enrollment and at 6 months after enrollment
Physical activity	The physical activity would be measured as the total time (minutes) of activity per user, retrieved by GoogleFit in the app.	Up to 6 months

Collaborators and Investigators

• Sponsor: Taipei Medical University

Publications and helpful links

General Publications

• Hors-Fraile S, Malwade S, Spachos D, Fernandez-Luque L, Su CT, Jeng WL, Syed-Abdul S, Bamidis P, Li YJ. A recommender system to quit smoking with mobile motivational messages: study protocol for a randomized controlled trial. Trials. 2018 Nov 9;19(1):618. doi: 10.1186/s13063-018-3000-1.

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2017
• Primary Completion (Actual): March 2, 2019
• Study Completion (Actual): March 15, 2019

Study Registration Dates

• First Submitted: March 24, 2017
• First Submitted That Met QC Criteria: April 5, 2017
• First Posted (Actual): April 11, 2017

Study Record Updates

• Last Update Posted (Actual): April 10, 2019
• Last Update Submitted That Met QC Criteria: April 8, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Other Study ID Numbers: N201702069

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No